Advancing Targeted Therapies Using The Foundation Trinity™
Technology in the War on Cancer
Advanced Proteome Therapeutics has developed a patent-pending technology that combines multiple anti-cancer therapies in a single agent to directly target cancer tumors. This type of agent, carrying multiple anti-cancer therapies, has exhibited greater potency, higher specificity, and less toxicity than individual therapies that can also attack healthy cells.
Our technology is based on a proprietary protein modification platform that can be used to attach entities to therapeutic proteins to enhance their properties and/or endow them with additional functions. Overall, our proprietary technology is based on "The Foundation Trinity™", which utilizes targeted therapy, combination therapy, and immunotherapy, in a single agent of high purity. Advanced, targeted therapies such as ours are intended to attack primarily cancer cells and are expected to dominate the anti-cancer therapeutics market in the near future.
CEO CFO Magazine Report
Advanced Proteome Therapeutics Corp is focused on developing a Protein Therapeutic that is Targeted and Combines Multiple Anti-Cancer Therapies for Greater Potency,
Higher Specificity and Less Toxicity than Individual Therapies
Targeted Cancer Therapeutics and Immunotherapy
A 4 minute video interview with Dr. Allen Krantz and a visit to the company's lab.